文献速递肿瘤 PET/CT核素与放射性配体治疗

肽基与纳米抗体基放射性示踪剂检测非小细胞肺癌PD-L1表达的头对头比较

Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-08

本研究纳入10例非小细胞肺癌患者,比较肽基示踪剂[68Ga]Ga-DOTA-WL12与纳米抗体基示踪剂[68Ga]Ga-NOTA-RW102 PET/CT显像,其中4例另接受[18F]FDG PET/CT。两种示踪剂在肝、肾、脾和肺背景的摄取差异有统计学意义(P<0.05),[68Ga]Ga-DOTA-WL12的SUVmax与PD-L1 TPS相关性显著更强。

要点

  • 10例非小细胞肺癌患者行[68Ga]Ga-DOTA-WL12与[68Ga]Ga-NOTA-RW102 PET/CT,4例另行[18F]FDG PET/CT。
  • 两种示踪剂在肝、肾、脾、肺背景的SUVmean差异均有统计学意义(P=0.015)。
  • [68Ga]Ga-DOTA-WL12的SUVmax与PD-L1 TPS相关性显著强于[68Ga]Ga-NOTA-RW102。

核心结论

  • 肽基[68Ga]Ga-DOTA-WL12的摄取与原发及转移肿瘤病灶PD-L1 TPS的相关性强于[68Ga]Ga-NOTA-RW102。
  • 两种示踪剂分布不同,提示肽基与纳米抗体基放射性示踪剂可能有不同的临床意义,尤其在放疗方面。

研究设计与样本

  • 10例确诊非小细胞肺癌患者接受[68Ga]Ga-DOTA-WL12与[68Ga]Ga-NOTA-RW102 PET/CT扫描,其中4例同时接受[18F]FDG PET/CT扫描。
  • 比较两种示踪剂PET/CT的SUVmax、SUVmean和靶本比(TBR)。

主要发现

  • DOTA-WL12与NOTA-RW102与PD-L1的结合亲和力良好,平衡解离常数(KD)分别为0.2 nM和0.0047 nM。
  • 肝SUVmean:DOTA-WL12组20.43 ± 4.26 vs NOTA-RW102组6.12 ± 1.36,P=0.015。
  • 肾SUVmean:DOTA-WL12组2.40 ± 0.34 vs NOTA-RW102组22.37 ± 2.88,P=0.015。
  • 脾SUVmean:DOTA-WL12组2.44 ± 0.67 vs NOTA-RW102组18.49 ± 3.90,P=0.015。
  • 肺背景SUVmean:DOTA-WL12组0.18 ± 0.12 vs NOTA-RW102组1.09 ± 0.29,P=0.015。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy based on programmed cell death protein receptor 1 and its ligand (PD-1/PD-L1) has become an important method for treating non-small cell lung cancer (NSCLC). Peptide-based and nanobody-based PET tracers offer potential advantages in PD-L1 detection, yet their comparative tumor uptake and biodistribution remain unclear. This study aimed to evaluate and compare [68Ga]Ga-DOTA-WL12 (a peptide-based tracer) and [68Ga]Ga-NOTA-RW102 (a nanobody-based tracer) in assessing PD-L1 expression in primary and metastatic NSCLC, providing insights for future radiotracer design and theranostic applications. METHODS: Ten patients diagnosed with NSCLC underwent [68Ga]Ga-DOTA-WL12 and [68Ga]Ga-NOTA-RW102 PET/CT scans, with four of these patients also receiving [18F]FDG PET/CT scans. The tracer uptakes, quantified by maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and target-to-background ratio (TBR), were compared between [68Ga]Ga-DOTA-WL12 and [68Ga]Ga-NOTA-RW102 PET/CT. RESULTS: DOTA-WL12 and NOTA-RW102 exhibited favorable binding affinities with PD-L1, with equilibrium dissociation constant (KD) values of 0.2 nM and 0.0047 nM, respectively. Subsequent human studies revealed significant variations (P < 0.05) in the uptake of [68Ga]Ga-DOTA-WL12 and [68Ga]Ga-NOTA-RW102 across the liver (SUVmean: 20.43 ± 4.26 vs. 6.12 ± 1.36, p = 0.015), kidney (SUVmean: 2.40 ± 0.34 vs. 22.37 ± 2.88, P = 0.015), spleen (SUVmean: 2.44 ± 0.67 vs. 18.49 ± 3.90, P = 0.015), and lung background (SUVmean: 0.18 ± 0.12 vs. 1.09 ± 0.29, P = 0.015). Meanwhile, we found that the correlation between SUVmax and PD-L1 TPS was significantly stronger with [68Ga]Ga-DOTA-WL12 compared to [68Ga]Ga-NOTA-RW102 (P < 0.0001, r = 0.9471 vs. P = 0.0241, r = 0.5235). CONCLUSION: The uptake of peptide-based [68Ga]Ga-DOTA-WL12 was more strongly correlated with PD-L1 TPS in primary and metastatic tumor lesions compared to [68Ga]Ga-NOTA-RW102. They also displayed different distribution, suggesting that peptide-based and nanobody-based radiotracers may have different clinical implications, particularly in radiotherapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu Y, Wang H, Gu Y, et al. Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40338301. doi:10.1007/s00259-025-07316-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。